Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR

Aminopeptidase inhibitors are receiving attention as combination chemotherapeutic agents for the treatment of refractory acute myeloid leukemia. However, the factors determining therapeutic efficacy remain elusive. Here we identified the molecular basis of acquired resistance to CHR2863, an orally a...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Verbrugge, Sue Ellen, Al, Marjon, Assaraf, Yehuda G., Kammerer, Sarah, Chandrupatla, Durga M.S.H., Honeywell, Richard, Musters, Rene P.J., Giovannetti, Elisa, O'Toole, Tom, Scheffer, George L., Krige, David, de Gruijl, Tanja D., Niessen, Hans W.M., Lems, Willem F., Kramer, Pieternella A., Scheper, Rik J., Cloos, Jacqueline, Ossenkoppele, Gert J., Peters, Godefridus J., Jansen, Gerrit
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2015
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4868683/
https://ncbi.nlm.nih.gov/pubmed/26496029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6169
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak